2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-143793
    RBP4 inhibitor 1 1198180-03-8 99.49%
    RBP4 inhibitor 1 (compound 43b) is a potent and orally active retinol-binding protein 4 (RBP4) inhibitor with IC50s of 28 nM and 110 nM for human and mouse RBP4. RBP4 inhibitor 1 has a potent and long-lasting blood RBP4-level-reducing effect in mice.
    RBP4 inhibitor 1
  • HY-147394
    GPR41 agonist-1 506417-09-0 98.04%
    GPR41 agonist-1 (compound 9) is a potent GPR41 agonist. GPR41 agonist-1 can be used for researching insulin-related disorders.
    GPR41 agonist-1
  • HY-151229
    S-Methyl-N,N-diethylthiolcarbamate 686-07-7 99.77%
    S-Methyl-N,N-diethylthiolcarbamate (DETC-Me; DDTC-Me) is the active metabolite of the aldehyde dehydrogenase inhibitor disulfiram (HY-B0240). It is produced by the methylation of the disulfiram metabolite diethyldithiocarbamate in mouse liver microsomes. S-Methyl-N,N-diethylthiolcarbamate (DETC-Me; DDTC-Me) inhibits rat liver low Km aldehyde dehydrogenase (ALDH) (ID50=15.5 mg/kg). When administered at a dose of 20.6 mg/kg, it decreases mean arterial pressure (MAP) and increases heart rate in rats during ethanol stimulation.
    S-Methyl-N,N-diethylthiolcarbamate
  • HY-151481
    FXR antagonist 1 2295804-68-9 99.85%
    FXR antagonist 1 (compound F6) is an orally active and selective intestinal FXR antagonist (IC50=2.1 μM). FXR antagonist 1 selectively inhibits intestinal FXR signalling through antagonism of intestinal FXR and feedback activation of hepatic FXR to improve hepatic steatosis, inflammation and fibrosis in NASH (nonalcoholic steatohepatitis) models. FXR antagonist 1 can be used in NASH studies.
    FXR antagonist 1
  • HY-151807
    15-PGDH-IN-1 2241676-74-2 98.35%
    15-PGDH-IN-1 is a potent and orally active 15-PGDH inhibitior. 15-PGDH-IN-1 has inhibition activity against recombinant human 15-PGDH with an IC50 value of 3 nM. 15-PGDH-IN-1 can be used for the research of tissue repair and regeneration.
    15-PGDH-IN-1
  • HY-153530
    LI-2242 2762762-17-2 98.95%
    LI-2242 is an inositol hexakisphosphate kinase (IP6K) inhibitor. LI-2242 has inhibition effect for IP6K1, IP6K2, IP6K3 and IPMK with IC50 values of 31 nM, 42 nM, 8.7 nM and 1944 nM, respectively. LI-2242 can be used for thew research of type II diabetes, obesity, metabolic complications, venous thrombosis, and psychiatric disorders.
    LI-2242
  • HY-155363
    AMPK activator 13 98.78%
    AMPK activator 13 is a potent activator of AMPK. AMPK activator 13 inhibits mitotic clonal expansion of 3T3-L1 cells by activating AMPK pathway and enhances cell mitochondrial oxygen consumption rate. AMPK activator 13 can be used in study obesity.
    AMPK activator 13
  • HY-161875
    NAT1-IN-1 99.77%
    NAT1-IN-1 (compound 350) is a potent N-acetyltransferase 1 (NAT1)-targeted inhibitor, with an IC50 of 44 nM. NAT1-IN-1 can be used for the research of hypermetabolic diseases such as amyotrophic lateral sclerosis, cancer cachexia, and sepsis.
    NAT1-IN-1
  • HY-161993
    BI-9787 3043939-18-7 99.46%
    BI-9787 is a zwitterionic inhibitior for ketohexokinase, with an IC50 of 12 and 12.8 nM for hKHK-A and hKHK-C. BI-9787 exhibits good metabolic stability in rat hepatocyte and good pharmacokinetic characteristics in rats.
    BI-9787
  • HY-163649
    A17 2568186-47-8 99.4%
    A17 is a bile acid analog with anti-non-alcoholic steatohepatitis (NASH) and anti-inflammatory activities. A17 reduces fatty acid (FA) uptake and promotes FA oxidation though inhibiting fatty acid translocase (Cd36) expression and activating AMPKα. A17 can be used for NASH research.
    A17
  • HY-164082
    Methyl clofenapate 21340-68-1 99.04%
    Methyl clofenapate (Clofenapate methyl ester; MCP) is a peroxisome proliferator, which can induce hypolipidemia, peroxisome proliferation, and hepatocarcinogenesis.
    Methyl clofenapate
  • HY-164740
    Plozasiran 2379776-40-4 99.00%
    Plozasiran is an siRNA targeting APOC3 for the study of mixed hyperlipidemia.
    Plozasiran
  • HY-164838
    ABC47 1831135-57-9 99.80%
    ABC47 is a potent inhibitor of serine hydrolases. ABC47 shows IC50s of 0.03 and 0.1 μM for ABHD4 and ABHD3, respectively. ABC47 plays an important role in infantile neuronal ceroid lipofuscinosis research.
    ABC47
  • HY-165099
    C-8 Ceramide-1-phosphate 158983-53-0 ≥98.0%
    C-8 Ceramide-1-phosphate is a cell apoptosis inhibitor and a cell survival inducer that can stimulate DNA synthesis and cell division. C-8 Ceramide-1-phosphate can inhibit acidic sphingomyelinase (SMase) and stimulate PI3-K, which in turn produces PIP3; PIP3 can also inhibit acidic SMase. The C-8 Ceramide-1-phosphate and ceramide can be interconverted in cells through kinase and phosphatase activity, and maintaining the balance between the two is crucial for cellular and tissue homeostasis.
    C-8 Ceramide-1-phosphate
  • HY-168046
    ALG-055009 2542029-03-6
    ALG-055009 is a selective and orally active Thyroid Hormone Receptor Beta (THR-β) agonist with an EC50 of 0.063 μM. ALG-055009 binds to the T3 hormone pocket of human THR-β, forming polar interactions with protein residues. ALG-055009 can lower total cholesterol levels in rats on a high-fat diet. ALG-055009 exhibits high metabolic stability, good permeability, a long in vivo half-life, and limited drug-drug interaction liability. ALG-055009 can be used in studies related to metabolic dysfunction-associated fatty liver disease.
    ALG-055009
  • HY-169266
    BRD-K56819078 693231-07-1 99.93%
    BRD-K56819078 is a Bcl-2 inhibitor that significantly reduces senescent cell load and senescence-related genes in the kidney mRNA expression. BRD-K56819078 exerts anti-aging effects by inhibiting apoptosis.
    BRD-K56819078
  • HY-174166
    AqF026 1021869-59-9 99.05%
    AqF026 is an aquaporin 1 (AQP1) agonist. AqF026 enhances the channel activity of human AQP1 in the Xenopus laevis oocyte system. AqF026 enhances the osmotic transport of water across the peritoneum in a mouse model of peritoneal dialysis. AqF026 can be used in studies related to ultrafiltration failure in peritoneal dialysis.
    AqF026
  • HY-175416
    Yoda2 3081450-95-2 99.57%
    Yoda2 (KC289), the potassium salt of Yoda1 (HY-18723), is a PIEZO1 agonist with an EC50 of 150 nM. Yoda2 evokes Ca2+ elevation and NO-dependent relaxation. Yoda2 induces relaxation in mouse arterial and cavernous tissues. Yoda2 inhibits glucocorticoid-induced osteoclast formation and bone resorptive activity, reverses glucocorticoid-induced bone density loss and architectural deterioration, and does not induce medication-related osteonecrosis of the jaw in mice. Yoda2 can be used for the researches of hypertension and osteoporosis.
    Yoda2
  • HY-176040
    IXA62 956783-34-9 99.55%
    IXA62 is an orally active and selective IRE1/XBP1s activator (EC50 = 0.31 μM) that reduces Aβ secretion. IXA62 enhances glucose-stimulated insulin secretion from rat insulinoma cells.
    IXA62
  • HY-B0135R
    Furosemide (Standard) 54-31-9 99.95%
    Furosemide (Standard) is the analytical standard of Furosemide. This product is intended for research and analytical applications. Furosemide is a potent and orally active inhibitor of Na+/K+/2Cl- (NKCC) cotransporter, NKCC1 and NKCC2. Furosemide is also a GABAA receptors antagonist and displays 100-fold selectivity for α6-containing receptors than α1-containing receptors. Furosemide acts as a loop diuretic and used for the study of congestive heart failure, hypertension and edema.
    Furosemide (Standard)
Cat. No. Product Name / Synonyms Application Reactivity